The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Positive Crossmatch Kidney Transplant Recipients Treated With Eculizumab: Outcomes Beyond 1 Year
Open accessAbstract
This study examined outcomes beyond 1 year in eculizumab-treated (EC) positive crossmatch kidney transplants (+XMKTx) compared to a historical control group. +XMKTx received desensitization with either plasma exchange (PE) alone (N = 48) or PE and EC (N = 30). EC, given for at least 1 month, was continued in the setting of persistently high DSA (B flow cytometric crossmatch [BFXM] >200) including: 4 weeks (n = 14); 9 weeks (n = 6), 6 months (n = 2), and 12 months (n = 8). All patients had at least 2 years follow-up. The incidence of acute clinical ABMR was lower in the EC group than controls (6.7% vs. 43.8% p < 0.01). Death-censored allograft survival was similar between groups. Chronic ABMR was the main cause of graft loss. On 1-year protocol biopsies, no differences were noted between EC and controls including: cg score >0, 26.7% versus 31.9% (p = 0.62), ptc score ≥ 2, 60.0% versus 60.0% (p = 1.00), or C4d + , 33.8% versus 13.5% (p = 0.08). A persistently high BFXM in EC-treated patients was associated with cg score >0 at 1 year, while EC appeared to protect against cg if the BFXM remained low. We conclude that despite decreasing acute clinical ABMR rates, EC treatment does not prevent chronic ABMR in recipients with persistently high BFXM after +XMKTx.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement and its role in innate and adaptive immune responses
Dunkelberger, J. R., & Song, W.-C. (2010) · Cell Research · doi:10.1038/cr.2009.139 · Cited by 1,932
The role of the anaphylatoxins in health and disease
Klos, A., Tenner, A. J., Johswich, K.-O., Ager, R. R., Reis, E. S., & Köhl, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.027 · Cited by 730 · cited 1×
“C3a is a potent chemotactic molecule that may stimulate an inflammatory response in the allograft independent of the blockade of C5 (21,22).”
Background
Cited by
Complement in disease: a defence system turning offensive
Ricklin, D., Reis, E. S., & Lambris, J. D. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.70 · Cited by 550
Antibody-Mediated Rejection of Solid-Organ Allografts
Loupy, A., & Lefaucheur, C. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1802677 · Cited by 549
The renaissance of complement therapeutics
Ricklin, D., Mastellos, D. C., Reis, E. S., & Lambris, J. D. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.156 · Cited by 379
Schinstock, C. A., Mannon, R. B., Budde, K., Chong, A. S., Haas, M., Knechtle, S., Lefaucheur, C., Montgomery, R. A., Nickerson, P., Tullius, S. G., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003095 · Cited by 345
Self-citationDonor-Specific Antibodies in Kidney Transplant Recipients
Zhang, R. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00700117 · Cited by 290
Winthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.002 · Cited by 259
Muduma, G., Odeyemi, I., Smith-Palmer, J., & Pollock, R. F. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0292-y · Cited by 35
Metadata
- Authors
- Cornell, L. D., Schinstock, C. A., Gandhi, M. J., Kremers, W. K., & Stegall, M. D.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 15
- Issue
- 5
- Pages
- 1293-1302
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1923404879
- Cited by
- 199
- References
- 2
- FWCI
- 24.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.